Amphastar Pharmaceuticals AMPH Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $720.53M-1.4% | $719.89M-1.7% | $723.31M0.0% | $722.68M+1.4% | $730.66M+8.1% | ||
| $379.4M+4.9% | $363.83M+1.6% | $366.27M+7.7% | $362.35M+12.2% | $361.65M+17.1% | ||
| $341.13M-7.6% | $356.06M-4.8% | $357.04M-6.9% | $360.33M-7.6% | $369.01M+0.4% | ||
| 47.3%-3.2pp | 49.5%-1.6pp | 49.4%-3.6pp | 49.9%-4.8pp | 50.5%-3.8pp | ||
| $92.49M+20.2% | $85.84M+16.1% | $80.67M+5.9% | $79.4M+10.6% | $76.97M+8.5% | ||
| $43.95M+9.1% | $43.89M+16.1% | $44.03M+22.3% | $41.52M+24.3% | $40.3M+29.5% | ||
| $87.96M+54.2% | $85.93M+51.5% | $82.39M+44.8% | $57.75M+5.5% | $57.04M+6.2% | ||
| $224.39M+28.7% | $215.65M+28.0% | $207.09M+22.5% | $178.66M+11.7% | $174.3M+11.9% | ||
| $224.39M+28.7% | $215.65M+28.0% | $207.09M+22.5% | $178.66M+11.7% | $174.3M+11.9% | ||
| $116.74M-40.0% | $140.4M-31.7% | $149.94M-30.0% | $181.67M-21.0% | $194.7M-8.0% | ||
| 16.2%-10.4pp | 19.5%-8.6pp | 20.7%-8.9pp | 25.1%-7.1pp | 26.6%-4.6pp | ||
| $25.75M-8.1% | $25.48M-16.0% | $25.28M-24.3% | $25.69M-36.4% | $28.02M-20.8% | ||
| $8.99M-11.4% | $8.68M-18.2% | $8.55M-19.5% | $8.73M-7.1% | $10.15M+43.1% | ||
| -$13.93M+36.6% | -$16.78M-7.2% | -$14.27M+47.4% | -$19.83M+26.0% | -$21.95M+15.2% | ||
| $102.81M-40.5% | $123.62M-34.9% | $135.67M-27.5% | $161.84M-20.3% | $172.75M-7.0% | ||
| $23.59M-24.2% | $25.53M-14.0% | $24.04M-15.2% | $27.13M-22.7% | $31.12M+6.6% | ||
| $79.23M-44.1% | $98.09M-38.5% | $111.63M-29.2% | $134.71M-19.1% | $141.63M-8.4% | ||
| 11%-8.4pp | 13.6%-8.2pp | 15.4%-6.4pp | 18.6%-4.7pp | 19.4%-3.5pp | ||
| $1.66-39.9% | $2.03-33.7% | $2.26-24.9% | $2.67-15.0% | $2.76-4.8% | ||
| $1.71-41.4% | $2.10-36.2% | $2.36-27.4% | $2.81-18.1% | $2.92-8.7% | ||
| 190.5M-7.5% | 193.9M-7.2% | 197.8M-5.8% | 201.9M-4.7% | 205.9M-3.4% | ||
| 185.5M-4.2% | 187.8M-3.3% | 189.5M-2.3% | 191.6M-1.3% | 193.6M0.0% | ||
| $2.83M+169% | $23K-99.4% | $2.46M+156% | -$2.87M-168% | -$4.08M-271% | ||
| $116.74M-40.0% | $140.4M-31.7% | $149.94M-30.0% | $181.67M-21.0% | $194.7M-8.0% | ||
| $174.17M-29.9% | $197.1M-23.7% | $205.73M-22.8% | $236.73M-15.9% | $248.3M-3.0% | ||
| $174.17M-29.9% | $197.1M-23.7% | $205.73M-22.8% | $236.73M-15.9% | $248.3M-3.0% | ||
| 24.2%-9.8pp | 27.4%-7.9pp | 28.4%-8.4pp | 32.8%-6.7pp | 34%-3.9pp | ||
| $116.74M-40.0% | $140.4M-31.7% | $149.94M-30.0% | $181.67M-21.0% | $194.7M-8.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Amphastar Pharmaceuticals's revenue?
- Amphastar Pharmaceuticals (AMPH) generated $720.5M in revenue over the trailing twelve months, down 1.4% year over year.
- Is Amphastar Pharmaceuticals profitable?
- Amphastar Pharmaceuticals reported $79.2M in net income over the trailing twelve months, a 11.0% net margin.
- What are Amphastar Pharmaceuticals's profit margins?
- Gross margin is 47.3% and operating margin is 16.2%, with a 11.0% net margin.
- What is Amphastar Pharmaceuticals's earnings per share?
- Amphastar Pharmaceuticals's diluted EPS over the trailing twelve months is $1.66.
- Where does Amphastar Pharmaceuticals's income statement data come from?
- Every line is extracted from Amphastar Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
